Bayer strengthens pharmaceutical business in India
Signs joint venture agreement with Zydus Pharma
Bayer HealthCare and Indian pharmaceutical firm Zydus Cadila have formed a joint venture company called Bayer Zydus Pharma to sell drugs in India.
The 50:50 joint venture, headquartered in Mumbai, will operate in the key segments of women’s healthcare, diagnostic imaging, cardiovascular diseases, anti-diabetic treatments, and oncology.
‘With this step, we aim significantly to accelerate our capabilities better serve the fast-growing Indian market,’ said Jörg Reinhardt, ceo of Bayer HealthCare.
The new company will combine Zydus Cadila’s marketing and sales expertise in India, as well as its distribution network, with Bayer HealthCare’s launch of new products and sales of existing brands.
In total Bayer Zydus Pharma will employ around 600 people from both companies.
Bayer Zydus Pharma's future product portfolio will not only include in-licensed and proprietary brands, but also patented pharmaceuticals from Bayer HealthCare’s pipeline. The combined portfolio will encompass, among others, brands such as Glucobay, Xarelto, Nexavar and Yaz/Yasmin from Bayer HealthCare, as well as products currently marketed by Zydus Cadila such as Euglim, Progynova and Ultravist.